Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19

Xabier García-Albéniz1,2 · Julia del Amo3 · Rosa Polo3 · José Miguel Morales-Asencio4 · Miguel A Hernán2,5,6

Abstract
Background Recruitment into randomized trials of hydroxychloroquine (HCQ) for prevention of COVID-19 has been adversely affected by a widespread conviction that HCQ is not effective for prevention. In the absence of an updated systematic review, we conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19.

Methods A search of PubMed, medRxiv, and clinicaltrials.gov combined with expert consultation found 11 completed randomized trials: 7 pre-exposure prophylaxis trials and 4 post-exposure prophylaxis trials. We obtained or calculated the risk ratio of COVID-19 diagnosis for assignment to HCQ versus no HCQ (either placebo or usual care) for each trial, and then pooled the risk ratio estimates.

Results The pooled risk ratio estimate of the pre-exposure prophylaxis trials was 0.72 (95% CI: 0.58–0.90) when using either a fixed effect or a standard random effects approach, and 0.72 (95% CI: 0.55–0.95) when using a conservative modification of the Hartung-Knapp random effects approach. The corresponding estimates for the post-exposure prophylaxis trials were 0.91 (95% CI: 0.72–1.16) and 0.91 (95% CI: 0.62–1.35). All trials found a similar rate of serious adverse effects in the HCQ and no HCQ groups.

Discussion A benefit of HCQ as prophylaxis for COVID-19 cannot be ruled out based on the available evidence from randomized trials. However, the “not statistically significant” findings from early prophylaxis trials were widely interpreted as definite evidence of lack of effectiveness of HCQ. This interpretation disrupted the timely completion of the remaining trials and thus the generation of precise estimates for pandemic management before the development of vaccines.

Background

Hydroxychloroquine (HCQ) is not an effective treatment for established coronavirus disease 2019 (COVID-19) [1, 2], but it is unclear whether HCQ can prevent symptomatic COVID-19. Early in the SARS-CoV-2 pandemic, about 30 randomized trials were designed to study HCQ as prophylaxis for COVID-19 [3]. After the findings from two of these trials were reported in the Summer of 2020 [4, 5], HCQ was generally viewed by the medical community as ineffective for COVID-19 prophylaxis. The emergence of that consensus was surprising because both trials found a lower risk of COVID-19 in the HCQ group, though they were too small to rule out either benefit or harm of HCQ.

A timely completion of the remaining trials would have generated precise estimates of the potential effectiveness of HCQ for prevention.
of HCQ to prevent COVID-19 among those at high risk of infection or complications. However, the widespread conviction about HCQ’s lack of effectiveness dramatically slowed down the recruitment into ongoing trials of HCQ prophylaxis (one of them carried out by the authors of this report) [6]. As a result, key decisions were made based on insufficient evidence during the pre-vaccine period of the pandemic.

We conducted a systematic review and meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19 either before known exposure to an infected individual (pre-exposure prophylaxis) or after known exposure to an infected individual (post-exposure prophylaxis).

**Methods**

Studies were eligible for inclusion if they were randomized clinical trials comparing hydroxychloroquine as prophylaxis (pre-exposure or post-exposure) for COVID-19 with a non-active control, included individuals who had a polymerase chain reaction (PCR) negative test for SARS-CoV-2 at the time of treatment assignment, and had the full text published in a peer-reviewed journal or as a pre-print. Given the relatively small number of trials, we identified candidate studies through expert consultation and confirmed the findings with a search of PubMed, medRxiv and Clinicaltrials.gov as of March 20, 2022, using the search strategies described in the Appendix (first reported as part of a preprint on September 29, 2020 [7]). Two authors (XGA and MAH) independently reviewed the full text of the identified studies and extracted the data. Disagreements were resolved by consulting other co-authors (JdA, RP). Incomplete or unpublished data were requested from the investigators of each trial. The risk of bias of the included studies was assessed independently by 2 authors (XGA, MAH) using the “Rob 2” tool by the Cochrane Bias Methods Group [8].

For each of the identified trials, we obtained or calculated the risk ratio of COVID-19 for assignment to HCQ versus no HCQ (either placebo or usual care) among test-negative individuals at baseline. Our primary analysis is based on the definition of COVID-19 reported in the primary analysis of each study. In addition, we tried to harmonize the definition of COVID-19 across studies by conducting a separate meta-analysis for laboratory-confirmed symptomatic COVID-19.

We calculated, separately for pre- and for post-exposure prophylaxis studies, the pooled risk ratio estimate and its 95% confidence or compatibility interval (CI) using a fixed (or common) effect approach and two types of random effects approaches [9, 10]. Because the standard random effects method may yield an anticonservative (that is, too narrow) 95% CI [9], we also used the Hartung-Knapp random effects method [10], which has been shown to generally outperform the standard random effects method [11]. However, this latter method results in an even more anti-conservative 95% CI (narrower than the 95% CI from the standard method) when, as in our meta-analysis, the estimated between-study heterogeneity is small (tau-squared near zero) [12, 13]. We therefore used the Hartung-Knapp method with an ad hoc modification [14] designed to ensure that its 95% CI remains wider than that of the standard method, even though the resulting 95% CI is expected to be conservative (too wide) when, as in our meta-analysis, the number of studies is small [15]. We also computed prediction intervals [16]. The protocol of the review was not registered. All analyses were conducted in Stata (version 16.1; Stata Corporation, College Station, Texas, USA).

**Results**

Eighty-eight records were identified, of which 16 were duplicates. The screening excluded fifty-nine records because of lack of randomization, use of HCQ as treatment for COVID-19 or, in the case of records from clinical trials, the absence of published results. Of the remaining 13 reports, two were excluded because they found no incident events in the HCQ arm [17] or at all [18] (Supplementary Fig. 1 contains the PRISMA 2020 flow diagram). Eleven completed randomized trials were included in the meta-analysis: seven trials studied hydroxychloroquine as pre-exposure prophylaxis [19–25] and four as post-exposure prophylaxis [4, 5, 26, 27].

Table 1 summarizes the key design characteristics and effect estimates reported by each study. The primary outcome definition varied across trials, with some trials using the presence of symptoms with or without laboratory confirmation [4, 19, 23], others using laboratory-confirmed symptomatic COVID-19 [5, 17, 18, 24, 25, 27] and others laboratory-confirmed SARS-CoV-2 infection with or without symptoms [20, 21, 26]. Our risk of bias assessment identified the handling of incomplete ascertainment of the outcome and the exclusion of patients after randomization as possible sources of moderate bias (see Supplementary Table 1).

The seven pre-exposure prophylaxis trials were double-blinded, placebo-controlled trials that included healthcare workers with ongoing exposure to patients with COVID-19 [19–25]. The occurrence of COVID-19 was ascertained during a period between 4 and 12 weeks. Figure 1 shows the risk ratio estimates from the seven pre-exposure prophylaxis trials. The pooled risk ratio of COVID-19 for hydroxychloroquine vs. no hydroxychloroquine was 0.72 (95% CI: 0.58,
| Trial | Publication date | Sample size | HCQ dose | Primary Outcome Definition | Effect estimate (95% CI) | Percentage of patients fully adherent to treatment |
|-------|-----------------|-------------|----------|---------------------------|--------------------------|---------------------------------------------------|
| **Pre-exposure prophylaxis trials** | | | | | | |
| Rajasingham et al. (19) | September 2020* | 494 HCQ (arm 1) 495 HCQ (arm 2) 494 Placebo | Arm 1: 400 mg loading dose twice, then 400 mg once weekly for 12 weeks Arm 2: 400 mg loading dose twice, then 400 mg twice weekly for 12 weeks | PCR-confirmed COVID-19 or probable compatible illness | HR: 0.73 (0.48, 1.09), both HCQ arms combined | Not reported |
| Abella et al. (20) | September 2020 | 66 HCQ 66 Placebo | 600 mg daily for 56 days | PCR-confirmed SARS-CoV-2 infection, regardless of symptoms | RD: -0.3 (-8.9, 8.3) cases per 100 | 97% HCQ 98% placebo |
| Seet et al. (21) | April 2021 | 432 HCQ 619 ascorbic acid | 400 mg loading dose, then 200 mg daily for 42 days | PCR-confirmed SARS-CoV-2 infection, regardless of symptoms | RR: 0.70 (0.44, 0.97) | 71.4% HCQ 80.0% ascorbic acid |
| Rojas-Serrano et al. (25) | May 2021* | 62 HCQ 65 Placebo | 200 mg daily for 60 days | PCR-confirmed symptomatic COVID-19 | HR: 0.18 (0.21, 1.59) | Not reported |
| Syed et al. (22) | May 2021* | 48 HCQ arm 1 51 HCQ arm 2 55 HCQ arm 3 46 Placebo | Arm 1: 400 mg loading dose twice on day 1, then 400 mg weekly for 12 weeks Arm 2: 400 mg once every 3 weeks Arm 3: 200 mg once every 3 weeks | Unclear: “COVID-19-free survival” | Not reported | Calculated RR: 0.70 (0.19, 2.59) |
| Naggie et al. (23) | August 2021* | 683 HCQ 676 Placebo | 600 mg loading dose twice on day 1, then 400 mg daily for 29 days | Symptomatic COVID-19, PCR-confirmed or not | RD: -1.98 (-4.6, 0.9) cases per 100 | 94.4% HCQ 95.7% placebo |
| Grau-Pujol et al. (17) | November 2021 | 142 HCQ 127 Placebo | 400 mg daily x 4, then 400 mg weekly for 30 days | Laboratory-confirmed (seroconversion or positive PCR) symptomatic COVID-19 | | Not reported |
| Polo et al. (24) | March 2022 | 231 HCQ 223 Placebo | 200 mg daily for 12 weeks | | RR: 0.49 (0.00, 2.29) | 85% HCQ 86% placebo |
| **Post-exposure prophylaxis trials** | | | | | | |
| Boulware et al. (4) | June 2020 | 414 HCQ 407 Placebo | 800 mg on day 1, then 600 mg daily days 1–5 | Symptomatic COVID-19, PCR-confirmed or not, by day 14 | RD: -2.4 (-7.0, 2.2) cases per 100 | 75.4% HCQ 82.6% placebo |
| Mitja et al. (5) | July 2020* | 1225 HCQ 1300 Usual care | 800 mg day 1, then 400 mg daily days 1–6 | PCR-confirmed, symptomatic COVID-19 by day 14 | RR: 0.68 (0.34, 1.34) | 95.1% HCQ 97.5% usual care |
| Barnabas et al. (26) | December 2020 | 353 HCQ 336 ascorbic acid | 400 mg daily for 3 days, then 200 mg daily for 11 days | PCR-confirmed SARS-CoV-2 infection, regardless of symptoms | HR: 1.10 (0.73, 1.66) | 88.0% HCQ 87% ascorbic acid |
The corresponding pooled risk difference was $0.90$ (95% CI: $0.55, 0.95$) when using the ad hoc modification of the Hartung-Knapp approach. The 95% CIs were wider (Supplementary Figs. 2–3). Supplementary Table 2 contains the prediction intervals.

Four post-exposure prophylaxis trials included asymptomatic contacts of confirmed COVID-19 cases. The time from exposure to initiation of prophylaxis was relatively long: in one trial, about a third of participants were enrolled 4 days after exposure (none was enrolled later) [4]; in the other, about 10% of participants were enrolled 7 or more days after exposure [5]; in the third study, 8% of participants received a first dose 5 days or later after exposure [26]. For comparison, post-exposure prophylaxis for HIV is recommended in the first 6–72 h after the exposure [28, 29]. The occurrence of COVID-19 was ascertained during a period of 2 weeks. A fourth post-exposure prophylaxis trial was not labelled as such by the authors, but 60% of the participants reported contact with a COVID-19 positive patient before study entry (time from contact to study entry not reported) [27]. The pooled risk ratio of COVID-19 for assignment to hydroxychloroquine vs. no hydroxychloroquine was $0.91$ (95% CI: $0.62, 1.35$) when using the ad hoc modification of the Hartung-Knapp approach (Fig. 2). Supplementary Table 2 contains the prediction intervals.

All trials found a similarly low rate of serious adverse effects in the HCQ and no HCQ groups. As expected, the proportion of mild gastrointestinal side effects was greater in the HCQ group. Adherence to treatment was heterogeneous across trials (Table 1). A funnel plot of the included studies is presented in Supplementary Fig. 4.
Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of...

When considered together, the available pre-exposure prophylaxis randomized trials yield a point estimate of an approximately 28% lower risk of COVID-19 for assignment to HCQ compared with no HCQ among PCR-negative individuals at randomization. Any effect between approximately 45% and a 5% reduction in risk is highly compatible with the data from these trials. The pooled effect estimate for the post-exposure randomized trial was closer to the null and both substantial reduction and moderate increase in risk were highly compatible with the data from the trials.

The choice of between common effect and random effects approaches for meta-analysis had little impact on the point estimates because the statistical heterogeneity across studies, as measured by the $I^2$, was close to zero. In the pre-exposure prophylaxis trials, the period over which the outcome was ascertained varied by a maximum of only 4 weeks and, given the long half-life of HCQ, variations in the order of weeks are not expected to substantially alter the effect estimates.

Our pooled estimates are based on the design and analytic choices made by the investigators of each trial. Ideally, these investigators could coordinate analyses of individual-level data with standardized outcome definitions; corrections for differences in length of follow-up and treatment dose; adjustment for losses to follow-up and other deviations from protocol; and adoption of a more causally-interpretable meta-analytic approach. All but two pre-exposure prophylaxis trials used laboratory-confirmed infection as the primary outcome; the remaining trials, and one of the four post-exposure prophylaxis trials, used laboratory-confirmed infection as the primary outcome; the remaining trials, [19, 23], and one of the four post-exposure prophylaxis trials, [4],...

Fig. 1 Risk ratio estimates of COVID-19 for hydroxychloroquine vs. no hydroxychloroquine in randomized trials of pre-exposure prophylaxis, pooled and by study. These estimates are based on the definition of COVID-19 reported in the primary analysis of each study.

Discussion

When considered together, the available pre-exposure prophylaxis randomized trials yield a point estimate of an approximately 28% lower risk of COVID-19 for assignment to HCQ compared with no HCQ among PCR-negative individuals at randomization. Any effect between approximately 45% and a 5% reduction in risk is highly compatible with the data from these trials. The pooled effect estimate for the post-exposure randomized trial was closer to the null and both substantial reduction and moderate increase in risk were highly compatible with the data from the trials.

The choice of between common effect and random effects approaches for meta-analysis had little impact on the point estimates because the statistical heterogeneity across studies, as measured by the $I^2$, was close to zero. In the pre-exposure prophylaxis trials, the period over which the outcome was ascertained varied by a maximum of only 4 weeks and, given the long half-life of HCQ [30], variations in the order of weeks are not expected to substantially alter the effect estimates.

Our pooled estimates are based on the design and analytic choices made by the investigators of each trial. Ideally, these investigators could coordinate analyses of individual-level data with standardized outcome definitions; corrections for differences in length of follow-up and treatment dose; adjustment for losses to follow-up and other deviations from protocol [31]; and adoption of a more causally-interpretable meta-analytic approach [32]. All but two pre-exposure prophylaxis trials used laboratory-confirmed infection as the primary outcome; the remaining trials [19, 23], and one of the four post-exposure prophylaxis trials [4],...

Fig. 2 Risk ratio estimates of COVID-19 for hydroxychloroquine vs. no hydroxychloroquine in randomized trials of post-exposure prophylaxis, pooled and by study. These estimates are based on the definition of COVID-19 reported in the primary analysis of each study.
did not require laboratory confirmation and included some self-reported test results. Excluding them resulted in a similar point estimate (Supplement Fig. 2).

As the results of pre- and post-exposure prophylaxis trials appeared between June and September of 2020, the pooled point estimate hovered around a 20% reduction with increasingly narrower compatibility intervals (Fig. 3). Yet throughout this entire period the opinion of many medical researchers was that HCQ was ineffective for prevention and that additional trials were unnecessary. The point estimate moved to around 10% reduction in December 2020 after the publication of a post-exposure prophylaxis cluster-randomized study [26] with unusual findings (no outcomes were recorded among individuals with unavailable PCR at baseline, different proportion of individuals with negative PCR at baseline between randomized groups) that may explain the investigators’ decision to deviate from protocol to adjust for baseline variables [33]. The final pooled risk ratio estimate, including all pre- and post-exposure trials, was 0.80 (95% CI 0.68, 0.95) when using the standard random effects approach and 0.80 (95% CI 0.67, 0.97) when using the ad hoc modification of the Hartung-Knapp approach.

The pooled estimates in Fig. 3 combine pre- and post-exposure prophylaxis trials, under the assumption of a similar mechanism of action for both preventive approaches [30]. However, the long time from exposure to treatment initiation in the post-exposure trials (several days as opposed to the 48 h recommended for other viruses like HIV) weakens the case for pooling studies of pre- and post-exposure prophylaxis because the latter can resemble studies of early treatment. Therefore, as the number of completed randomized trials increased in 2021 and 2022, meta-analyses like ours need to present separate estimates for pre-exposure and post-exposure prophylaxis. Such distinction is not always easy: for example, one of the pre-exposure prophylaxis trials identified and isolated 346 PCR positive cases at baseline in the premises where the study was run [21].

This systematic review offers an important lesson for future research on drug repurposing: Recruitment for most trials of HCQ prophylaxis was severely impeded by

Fig. 3 Cumulative estimate of the pooled risk ratio of COVID-19 for hydroxychloroquine vs. no hydroxychloroquine in randomized trials of pre- and post-exposure prophylaxis. Confidence intervals are computed using the standard random effects method
incorrect interpretations of the evidence from the early, mostly post-exposure prophylaxis, trials. The findings from the first reported trials were widely (and incorrectly) portrayed as definite evidence of the lack of effectiveness of HCQ, simply because they were not “statistically significant” when taken individually. Thus, the common confusion between the concepts “no effect” and “no statistical significance” led many to prematurely conclude that HCQ had no prophylactic effect when the correct conclusion was that the effect estimate was too imprecise [34, 35].

Concerns about potentially deleterious effects of treatment with HCQ [36] and backlash against unsubstantiated claims in the lay media [37] may have also affected the timely completion of the prophylaxis trials. In one study [24], conversations with investigators in participating hospitals confirmed that recruitment was difficult because of toxicity concerns. Of four eligible trials labelled as “completed” or “terminated” in clinicaltrials.gov but without posted results (NCT04414241, NCT04374942, NCT04372017 and NCT04344379), at least one had to be terminated because of poor recruitment, and another was closed after recruitment of one patient because researchers considered that the risk/benefit balance of HCQ was unfavorable (personal communications from the investigators). Yet these safety concerns were unwarranted as demonstrated by the findings of the randomized trials included in our meta-analysis. We encourage the authors of living systematic reviews [38] to update their findings frequently when, as in this case, public opinion interferes with the generation of the very evidence that will feed their systematic review.

In summary, throughout much of the pre-vaccine period of the pandemic, the available evidence was compatible with HCQ being viable as prophylaxis. Yet an incorrect interpretation of early inconclusive studies interfered with recruitment into additional trials. Though the availability of effective COVID-19 vaccines reduces the need for pharmacological prophylaxis, it is important to improve the process by which the medical community generates and interprets evidence before the next public health emergency arrives. To avoid the proliferation of small studies with different methodologies, national regulators and international health organizations can play a key role in the coordination and harmonization of the design of the randomized trials that they approve or endorse.

Acknowledgements We thank Sander Greenland and Daniel Westreich for technical advice, Matthew Cefalu for constructive feedback on study outcomes, and Richard Riley, Tim Morrison, and David Fisher for constructive feedback on estimation methods for random effects meta-analysis. We thank Ruanne Barnabas and Torin Schaafsm a for providing the risk ratio from their study for inclusion in this meta-analysis.

Author contribution XGA and MAH analysed the data and drafted the manuscript. All authors made substantial contributions to the design of the study, interpreted the data, revised the manuscript critically, approved the version to be published and agree to be accountable for all aspects of the work. Code is available upon request from Xabier Garcia-Albeniz (xgarcia@rti.org).

Funding No funding was received to support the development of this manuscript.

Declarations

Competing Interests The authors have no relevant financial or non-financial interests to disclose.

References

1. Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, García CH, et al. Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results. medRxiv. 2020;2020.10.15.20209817.
2. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030–40.
3. Bienvenu AL, Marty AM, Jones MK, Picot S. Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. One health (Amsterdam, Netherlands). 2020;10:100141.
4. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517–25.
5. Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebè C, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New England Journal of Medicine; 2020.
6. Goldman JD. Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. Clin Infect diseases: official publication Infect Dis Soc Am. 2021;72(11):e844-e7.
7. García-Albéniz X, Amo JD, Polo R, Morales-Asencio JM, Hernán MA. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. medRxiv. 2022-2020.09.29.20203869.
8. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
10. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001;20(24):3875–89.
11. InitiHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidak-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25.
12. Wiksten A, Räcker G, Schwarzer G. Hartung-Knapp method is not always conservative compared with fixed-effect meta-analysis. Stat Med. 2016;35(15):2503–15.
13. Jackson D, Law M, Rücker G, Schwarzer G. The Hartung-Knapp modification for random-effects meta-analysis: A useful refinement but are there any residual concerns? Stat Med. 2017;36(25):3923–34.
14. Röver C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. BMC Med Res Methodol. 2015;15(1):99.

15. Partlett C, Riley RD. Random effects meta-analysis: Coverage performance of 95% confidence and prediction intervals following REML estimation. Stat Med. 2017;36(2):301–17.

16. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137–59.

17. Grau-Pujol B, Camprubi-Ferrer D, Marti-Soler H, Fernández-Pardos M, Carreras-Abad C, Andrés MV-d, et al. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials. 2021;22(1):808.

18. Liu HH, Ezekowitz MD, Columbo M, Khan O, Martin J, Spahr J, et al. Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic. J Interv Card Electrophysiol. 2021:1–12.

19. Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America; 2020.

20. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA internal medicine. 2020.

21. Seet RCS, Quek AML, Ooi DSQ, Sengupta S, Lakshminarasappa SR, Koo CY, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. Int J Infect Dis. 2021;106:314–22.

22. Syed F, Arif MA, Niazi R, Baqar JB, Hashmi UL, Batool SA, et al. Pre-Exposure Prophylaxis with Various Doses of Hydroxychloroquine among high-risk COVID 19 Healthcare Personnel: CHEER randomized controlled trial. medRxiv. 2021:2021.05.17.21257012.

23. Naggie S, Milestone A, Castro M, Collins SP, Seetha L, Anderson DJ, et al. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ). medRxiv. 2021.08.19.21266275.

24. Polo R, García-Albéniz X, Terán C, Morales M, Rial-Crestelo D, Garcimuno M, et al. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. medRxiv. 2022:2022.03.02.22227170.

25. Rojas-Serrano J, Portillo-Vásquez AM, Thiron-Romo I, Vázquez-Pérez J, Mejia-Nepomuceno F, Ramírez-Venegas A, et al. Hydroxychloroquine for prophylaxis of COVID-19 in health care workers: A randomized clinical trial. PLoS ONE. 2022;17(2):e0261980.

26. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial. Ann Intern Med. 2020.

27. McKinnon JE, Wang DD, Z eros M, Saval M, Marshall-Nightengale L, Kilgore P, et al. Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study. Int J Infect Dis. 2022;116:167–73.

28. Kuhar DT, Henderson DK, Struble KA, Henein W, Thomas V, Cheever LW, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis.

29. [Consensus Document on post-exposure prophylaxis against HIV. HBV and HCV in adults and children]. Enferm Microbiol Clin. 2016;34(2):121.e1-15.

30. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect diseases: official publication Infect Dis Soc Am. 2020;71(15):732–9.

31. Hernan MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377(14):1391–8.

32. Dahabreh IJ, Petitto LC, Robertson SE, Hernán MA, Steinbrook RJ. Toward Causally Interpretable Meta-analysis: Transporting Inferences from Multiple Randomized Trials to a New Target Population. Epidemiology (Cambridge, Mass). 2020;31(3):334 – 44.

33. Barnabas RV, Brown E, Bershteyn A, Miller RS, Wener M, Celum C, et al. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):475.

34. Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567(7748):305–7.

35. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337–50.

36. Axfors C, Schmitt AM, Janiaud P, van’t Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349.

37. Niburski K, Niburski O. Impact of Trump’s Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study. J Med Internet Res. 2020;22(11):e20044.

38. Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Le G, et al. Prophylaxis against COVID-19: a double-blind placebocontrolled randomized trial. JAMA intern med. 2020.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10654-022-00891-4.